Virna Schuck

Virna Schuck is VP of Clinical Pharmacology at Acrivon Therapeutics. Virna has nearly 20 years of experience in the Pharmaceutical Industry, working across Research and Development. Prior to joining Acrivon, Virna held positions of increasing responsibility at Ribon Therapeutics, Certara, Novartis, AstraZeneca, and Millennium Pharmaceuticals. More recently, Virna worked as an independent consultant, providing strategic and tactical guidance on Clinical Pharmacology and Translational Medicine. Throughout her career, Virna had the opportunity to work across different functions including DMPK, pharmacology, nonclinical modeling and simulations and clinical pharmacology. She has experience with integrating nonclinical and clinical data to drive clinical pharmacology strategies in early development and executing on these strategies to support selection of clinical dose and regimen. She contributed to the discovery of Zoliflodacin, a first-in-class antibiotic, and the successful submissions of Tembexa® and Leqvio®.

Virna has a bachelor’s degree in Pharmacy and Masters in Pharmaceutical Sciences from the Federal University of Rio Grande do Sul – UFRGS- Brazil, and a PhD in Pharmaceutical Sciences from the College of Pharmacy, University of Florida.